Phaseline

Companies › HELP Therapeutics

HELP Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 3; Metabolic and endocrine, Cardiovascular; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
HiCM-188
Allogeneic human induced pluripotent stem cell-derived cardiomyocytes
–Phase 3Heart FailureNov 2026
HMM910
Human umbilical cord-derived mesenchymal stem cells
–Phase 1Osteoporosis in Post-menopausal Women–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06949137HMM910Phase 1Osteoporosis in Post-menopausal WomenMetabolic and endocrineMar 2026
NCT06340048HiCM-188Phase 1Heart FailureCardiovascularNov 2026
NCT07496372HiCM-188Phase 3Heart FailureCardiovascularJun 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Sirius Therapeutics Crystalys Therapeutics Vincentage Pharma RECORDATI GROUP Shanghai Minwei Biotechnology

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.